Safety and Efficacy of Moderate-dose Denosumab in Fibrous Dysplasia: Observational Results From a Phase 2 Clinical Trial Article

sustainable development goals

publication date

  • December 24, 2024

webpage

published in

keywords

  • McCune-Albright syndrome
  • denosumab
  • fibrous dysplasia
  • metabolic bone disease